The startup develops drug-coated balloon technology for gastroenterology, specifically targeting benign strictures in the esophagus and bowel. Their investigational device promotes sustained patency, minimizing the frequency of required treatments for affected patients.
Funding
$18M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Benign strictures in the esophagus and bowel often require repeated dilation procedures due to high rates of recurrence. Current dilation methods provide only temporary relief, leading to frequent and costly interventions for affected patients.
Solution
GIE Medical is developing the ProTractX3™ TTS drug-coated balloon (DCB) to address benign strictures of the esophagus and bowel. This investigational device delivers paclitaxel, an anti-restenotic agent, directly to the stricture site during dilation. By inhibiting cell proliferation, the DCB aims to promote sustained patency and reduce the need for repeat procedures. The ProTractX3 DCB is currently undergoing clinical trials to evaluate its safety and efficacy compared to standard balloon dilation.
Target Audience
The primary target audience includes gastroenterologists and other physicians treating patients with benign esophageal and bowel strictures.
Features
- Paclitaxel-coated balloon designed for targeted drug delivery during dilation
- Multi-stage balloon for uniform drug distribution
- Through-the-scope (TTS) delivery for minimally invasive procedures
- Clinical trials underway for esophageal (PATENT-E) and bowel (PATENT-B) strictures
- Granted FDA Breakthrough Device Designation for esophageal strictures